86-21-64556180
cpd-service@caerulumpharma.com

Farashin TLR8

da

Tuntube Mu

Tambaya

Sabbin Labarai

  • AstraZeneca yana karɓar haɓakar tsari don magungunan oncology

    AstraZeneca yana karɓar haɓaka tsari don ...

    AstraZeneca ta sami haɓaka ninki biyu don fayil ɗin cutar sankara a ranar Talata, bayan hukumomin Amurka da na Turai sun karɓi ƙa'idodin ƙa'idodin magungunanta, matakin farko na samun amincewar waɗannan magunguna. ...

  • Manyan Abubuwa 7 A cikin Binciken Magunguna A cikin 2018

    Manyan Abubuwa 7 A Cikin Binciken Magunguna Na...

    Kasancewar kasancewa ƙarƙashin matsin lamba don yin gasa a cikin yanayi mai ƙalubale na tattalin arziki da fasaha, dole ne kamfanonin harhada magunguna da fasahar kere-kere su ci gaba da haɓaka cikin shirye-shiryensu na R&D don ci gaba ...

  • ARS-1620: Sabuwar mai hanawa don KRAS-mutant cancers

    ARS-1620: Sabuwar mai hanawa don K ...

    A cewar wani binciken da aka buga a cikin Cell, masu bincike sun kirkiro wani takamaiman mai hanawa don KRASG12C mai suna ARS-1602 wanda ya haifar da koma baya a cikin mice. "Wannan binciken yana ba da shaida a cikin vivo shaida cewa mutant KRAS na iya zama ...

  • AstraZeneca yana karɓar haɓakar tsari don magungunan oncology

    AstraZeneca yana karɓar haɓaka tsari don ...

    AstraZeneca ta sami haɓaka ninki biyu don fayil ɗin cutar sankara a ranar Talata, bayan hukumomin Amurka da na Turai sun karɓi ƙa'idodin ƙa'idodin magungunanta, matakin farko na samun amincewar waɗannan magunguna. ...

  • Manyan Abubuwa 7 A cikin Binciken Magunguna A cikin 2018

    Manyan Abubuwa 7 A Cikin Binciken Magunguna Na...

    Kasancewar kasancewa ƙarƙashin matsin lamba don yin gasa a cikin yanayi mai ƙalubale na tattalin arziki da fasaha, dole ne kamfanonin harhada magunguna da fasahar kere-kere su ci gaba da haɓaka cikin shirye-shiryensu na R&D don ci gaba ...

    • prev
    next
© Haƙƙin mallaka - 2015-2022: Duk haƙƙin mallaka.
WhatsApp Online Chat!
Close
PreviousNext
PreviousMaximize
Next